Last reviewed · How we verify
NCT03742115
Etoposide in the First-line Treatment of Adult EBV-HLH
Phase 3 trial testing Etoposide in Hemophagocytic Lymphohistiocytosis in 90 participants. Status unknown.
1 December 2019
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 December 2018 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Etoposide (etoposide) — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
- Etoposide (etoposide) — full drug profile →
- IVIG — full drug profile →
Conditions studied
- Hemophagocytic Lymphohistiocytosis — all drugs for Hemophagocytic Lymphohistiocytosis →
Sponsor
Beijing Friendship Hospital
Who can join
Adults 18 to 75, any sex, with Hemophagocytic Lymphohistiocytosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
his study aimed to investigate the efficacy of etoposide as the first line therapy for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03742115
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Etoposide
Trials testing the same drug.
- NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
- NCT06406465 — A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity · Phase 2 · recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
- NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom · Phase 2 · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03742115 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 15 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03742115.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing